Circulating and Imaging Biomarkers in Lung Cancer Radiotherapy
Research type
Research Study
Full title
Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer (VIGILANCE)
IRAS ID
299279
Contact name
Corinne Faivre-Finn
Contact email
Sponsor organisation
University of Manchester
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Around 13,000 patients a year in the UK are diagnosed with stage III non-small lung cancer (NSCLC) with the majority being unsuitable for surgery. In suitably fit patients, treatment is usually chemo-radiotherapy followed by immunotherapy. Unfortunately, these treatments can be toxic for the patient to endure. In recent years, the treatment of cancer has been transformed with biological markers allowing clinicians to personalise treatment decisions to individual patients. For patients with stage III NSCLC, there is an unmet need to identify those who do not benefit from treatment. There is also a need to diagnose those patients who are going to relapse, before they have symptoms of disease or evidence of disease progression on a scan. We aim to find new markers in the blood and on routine scans that will predict both of these situations. This personalised approach will maximise chances of successful treatment.
REC name
North West - Preston Research Ethics Committee
REC reference
22/NW/0297
Date of REC Opinion
3 Oct 2022
REC opinion
Favourable Opinion